

Effective 12/8/25, the LymphoSeq assay will cover single nucleotide variants (SNVs) and insertions/deletions (indels) in 50 genes relevant to lymphoid malignancies: TET2, STAT6, ACTB, BIRC3, RHOA, ATM, B2M, BCL2, BCL6, BRAF, BTK, CCND3, CD79B, CDKN2A, CCR4, CREBBP, EZH2, IDH2, IL4R, ITPKB, JAK2, JAK3, JAK1, MYC, MYD88, NOTCH1, NFKBIE, NOTCH2, NRAS, PAX5, PIM1, PLCG2, MAP2K1, PTEN, SMARCA4, SMARCB1, STAT3, STAT5B, TP53, NSD2, CXCR4, KMT2D, ARID1A, SOCS1, IKZF1, KLF2, SF3B1, INO80, CARD11, MEF2B

FFPE samples will also evaluate for fusions in the following genes:

RET, FGFR2, BCL11B, NUTM1, DUX4, PAX5, CSF1R, FGFR1, FLT3, PTK2B, NTRK3, LYN, PDGFRA, P2RY8, HLF, PBX1, TCF3, IL3, RUNX1, ETV6, IGL, IGK, IGH, PDGFRB, EPOR, MEF2D, CRLF2, ABL2, ZNF384, KMT2A, ABL1, BCR, MALT1, BIRC3, JAK3, JAK2, MTCP1, TCL1A, MYC, BCL2, ALK, BCL6, IRF4, CIITA, NPM1, TP63, DUSP22, TBL1XR1